Peptriva Review

The lead

Peptriva scores 4.8 out of 5 on this record, and the two halves of that number matter more than the number. The release rule is stronger than the category standard: a lot cannot enter sellable stock until two separate certificates exist for it, and that requirement is enforced as a condition in the order system rather than promised in policy copy. The history behind the rule is thin. Fourteen certificates cover thirteen lots, and every independent certificate on file comes from a single submission, received on 30 June 2026 and reported on 2 July 2026^[1][2]. A supplier with years of archived batches has something this record does not have, and no amount of method design substitutes for it.

This publication reviews Peptriva as company #1 on its roster. What is offered here is the paperwork: certificates, accession numbers, dates, and the checks a reader can run without taking anyone's word for anything. On that documentary test, Peptriva is a shining example among research chemical suppliers^[8].

What we examined

Five bodies of evidence, in this order. The certificate ledger, read row by row, with the laboratory's reported purity, net content, endotoxin result, appearance, accession number, and date pair for every lot^[1]. The independent laboratory itself, which has a public presence separate from Peptriva, so the name printed on a certificate can be checked rather than assumed^[2]. The published terms of sale, including the returns position, the four claim windows, the Out-of-Spec Guarantee, the age gate, the governing law, and the research-use-only conditions^[3]. The shipping policy and the catalogue, for carrier, cut-off, processing, destinations, packaging, listed products, stock state, and price range^[4][5]. And the code path in the order system that decides whether a received lot becomes sellable inventory, which is where the release rule actually lives.

Where the storefront claims more than those documents support, this issue drops the claim rather than repeating it. That decision produced the section below headed "What did not survive", and it is the section a sceptical reader should read first.

What we found

Thirteen products are in stock, and thirteen of thirteen carry an independent third-party certificate^[1][5]. Forty products are listed in the catalogue, most of them not currently in stock, across categories that run from cytoprotective and copper peptides to mitochondrial, melanocortin, and lab consumables^[5].

The release rule is the finding that separates this record from the category. In the purchase-order sync that moves received inventory into sellable stock, the condition reads lotClearedToSell = lotHasManufacturerCoa() AND lotHasIndependentCoa(), in apps/backend/src/lib/sync-po-to-medusa.ts. The manufacturing facility tests and releases the batch, and that certificate is held on file. On arrival at the United States distribution facility a sample goes to Freedom Diagnostics of Franklin, Tennessee, for a full re-test, and that certificate is the one published^[1][2]. One exemption exists and is disclosed here rather than left to be discovered: the lab solvent clears on the independent certificate alone, because no production certificate is issued for an off-the-shelf USP solvent.

The panel behind those certificates is five assays: identity by LC-MS, purity by HPLC-UV reported as area percent, net content as a measured mass in the vial, bacterial endotoxin by LAL under USP General Chapter <85> run in duplicate against a specification of 0.05 EU/mL or lower, and appearance^[1][6]. Across the eight publishable lots, purity runs from 99.58 percent to 99.90 percent^[1]. The seller of record is identifiable: Wayne Ventures SEZC, a Cayman Islands company trading as Peptriva, shipping from 14516 Garfield Ave, Paramount, California 90723, with a published telephone number and support hours of Monday to Friday, 9am to 5pm CT^[3][7].

What we held back from

Four products sit on a restricted tier where active litigation risk in this category governs how a compound may be presented. Their certificates are real, public, and produced under the same five-assay panel by the same laboratory. This issue does not build tables or examples around them and does not reprint their figures, because a review property organised around those four compounds becomes a marketing surface for them whatever the surrounding text says. A reader who wants those numbers reads them at the ledger, where they have always been^[1].

Three further restraints apply throughout. No page here describes what any product does, because the panel measures chemistry and chemistry carries no implication about any biological outcome. No customer count, order count, or review average appears anywhere, because a figure of that kind published by the seller and unaudited is worth nothing as evidence. And no competitor is named in the comparison on the verdict page, which compares on method against the category norm rather than against a rival's marketing.

What did not survive

The storefront asserts laboratory accreditation in several places. No certificate, scope number, or accrediting body exists in anything Peptriva publishes to support it, so the assertion does not appear on this network. These pages say "independent third-party laboratory", name it, and stop there^[2]. That is the single largest claim dropped, and dropping it costs the record something real: an accreditation scope would be the load-bearing proof under the entire testing story, and its absence is a gap rather than a technicality.

Three smaller claims went the same way. No sterility claim survives, because no sterility assay is on the panel and the published terms state the material is not sterile^[3]. No cold-chain claim survives for the parcel: lyophilized material is stable at ambient temperature in transit and ships in standard parcel packaging, and the cold-chain description belongs to the distribution facility where the re-test happens, not to the box^[4]. No origin claim survives either, because this record does not describe the material as United States made. It describes where the material is tested and where it ships from, which are different questions^[4][7].

The verdict, in one line

Peptriva is a young supplier with an unusually well-designed release rule and an unusually short record of using it, and a reader who weighs method will find it convincing where a reader who weighs track record will not.